News 2015

Thuja Capital Healthcare Seed Fund II invests in Nutrileads

Date: 18/11/2015

18 November 2015, Utrecht – Thuja Capital today announced that it has invested in Wageningen-based Nutrileads, a start-up company active in the field of medical and functional foods. Thuja acted as lead investor, heading a syndicate of Shift Invest, PPMOost and DSM Venturing.  (more…)

arGEN-X completes first dosing of ARGX-113 for severe autoimmune disorders

Date: 22/10/2015

22 October 2015, Breda, The Netherlands / Ghent, Belgium – arGEN-X N.V. (Euronext Brussels: ARGX) today announces the completion of the first human dosing of ARGX-113, a potential breakthrough therapy for the treatment of autoimmune crisis. (more…)

Cristal Therapeutics starts clinical phase I trial with nanomedicine CriPec® docetaxel in patients with solid tumours

Date: 29/09/2015

29 September 2015, Maastricht, The Netherlands – Cristal Therapeutics, a privately-held life sciences company developing innovative drugs against cancer and other diseases, today announced the recent start of a clinical phase I trial with its lead candidate CriPec® docetaxel (more…)

arGEN-X’ partner RuiYi, Inc. announces first human dosing of gerilimzumab, a novel SIMPLE antibody™ against IL-6

Date: 23/09/2015

23 September 2015, Breda, The Netherlands / Ghent, Belgium – arGEN-X N.V. (Euronext Brussels: ARGX) today reports that its partner RuiYi, Inc., a company focused on the discovery and development of novel biologic therapies (more…)

TheraSolve Announces US Patent Issuance for MemoPatch®

Date: 15/09/2015

15 September 2015, Diepenbeek, Belgium – TheraSolve NV, a medication adherence innovator, announced today patent issuance from the United States Patent and Trademark Office for its innovative MemoPatch® reminder technology. (more…)

NightBalance strengthens competitive position in sleep apnea market with key US and EU patent for innovative Sleep Position Trainer

Date: 19/08/2015

19 August 2015, Delft, the Netherlands – Today the European Patent office has granted NightBalance an important patent for their “method and device for sleep posture correction”, following the earlier grant by the US Patent and Trademark Office on July 30th 2015. (more…)

arGEN-X and University of Bern enter into license agreement

Date: 30/07/2015

30 July 2015, Breda, The Netherlands/Ghent, Belgium – arGEN-X and the Clinical Research Department of the University of Bern announce an exclusive license agreement enabling arGEN-X to develop and commercialize ARGX-110-based therapies to overcome treatment resistance mechanisms in hematologic tumors. (more…)

Supersnelle scan verlicht reumaleed

Date: 25/07/2015

25 July 2015 – Article on Hemics in Algemeen Dagblad (Dutch national newspaper) (more…)

FABPulous wins €1.6m EU grant for clinical trials of 5 minute heart attack test

Date: 21/07/2015

20 July 2015, Maastricht (Netherlands) – The European Union awarded FABPulous BV a €1.6 million Phase 2 grant to fund two clinical trials in the UK and Belgium/Netherlands and automate the manufacture of its 5 minute, patented H-FABP True Rapid Test® (more…)

NightBalance patent for “method and device for sleep posture correction” granted by US PTO

Date: 01/07/2015

1 July 2015, Delft, the Netherlands – NightBalance BV, a leading innovator of obstructive sleep apnea (OSA) technology, announced today that the U.S. Patent and Trademark Office has granted (more…)

TheraSolve wins Biomedica 2015 Award for best Medtech Innovation

Date: 10/06/2015

9 June 2015, Diepenbeek (Belgium)  – TheraSolve NV presented its MemoPatch® reminder technology at the European Life Sciences Summit Biomedica 2015 and has been elected by the members of the Biomedica Foundation Board as winner in the category Medtech. (more…)

European Investment Fund makes formal funding commitment to TCHF II

Date: 02/06/2015

2 June 2015, Utrecht – Today the European Investment Fund (EIF) has communicated a formal commitment for an investment in Thuja Capital Healthcare Fund II. The commitment amounts to EUR 15M assuming a fund size of EUR 35M. (more…)

arGEN-X presents preliminary efficacy and expanded safety data from Phase I trial of ARGX-111 at ASCO

Date: 31/05/2015

31 May 2015 – Breda, The Netherlands. arGEN-X N.V. (Euronext Brussels: ARGX) will present the results of a Phase I, first-in-human dose escalation study of ARGX-111, (more…)

Cristal Therapeutics announces formation of Scientific Advisory Board

Date: 22/05/2015

22 May 2015 – Maastricht, The Netherlands – Cristal Therapeutics today announced the appointments of Prof. Dr. Rob Liskamp, Prof. Dr. Twan Lammers, Prof. Dr. Alberto Gabizon, Dr. Maninder Hora and Dr. William Zamboni (more…)

arGEN-X and LEO Pharma enter into alliance to develop antibody-based treatments for skin conditions

Date: 21/05/2015

21 May 2015 – Breda, the Netherlands/Ghent, Belgium – arGEN-X N.V. (Euronext Brussels: ARGX) and LEO Pharma A/S, a global healthcare company dedicated to helping people achieve healthy skin, today announced an alliance (more…)

arGEN-X awarded €1.5 million IWT grant

Date: 19/05/2015

19 May 2015 – Breda, The Netherlands / Ghent, Belgium – arGEN-X N.V. (Euronext Brussels: ARGX) today announced that it has received a € 1.5 million grant from the Institute for the Promotion of Innovation by Sciences and Technology in Flanders (IWT). (more…)

NightBalance receives coverage from largest Dutch healthcare payor Achmea for sleep apnea device

Date: 18/05/2015

18 May 2015, Delft, the Netherlands – NightBalance announced today that Achmea, the largest healthcare payor in the Netherlands covering 5 million lives, will reimburse its Sleep Position Trainer (SPT). (more…)

arGEN-X announces publication on therapeutic potential of antibody ARGX-115 in cancer immunotherapy

Date: 23/04/2015

23 April 2015 – Breda, The Netherlands – arGEN-X N.V. (Euronext Brussels: ARGX) today announced the publication of new data showing that the preclinical therapeutic antibody ARGX-115 blocks the activity of GARP, a novel immune checkpoint. (more…)

EE Times Europe magazine featuring article on TheraSolve

Date: 15/04/2015

The electronic magazine EE Times Europe, a magazine dedicated to electronics, has issued a special edition (April 2015) (more…)

arGEN-x N.V. Announces Changes to the Board of Directors

Date: 14/04/2015

14 April 2015, Breda, The Netherlands – arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies (more…)

arGEN-X EXPANDS PRECLINICAL PIPELINE WITH ARGX-115 FOR CANCER IMMUNOTHERAPY

Date: 06/03/2015

4 March 2015 – Breda, The Netherlands / Ghent, Belgium – arGEN-X N.V. (Euronext Brussels: ARGX) today announced that it has exercised its option to exclusively license a first-in-class, preclinical therapeutic antibody candidate, (more…)

Lonza and arGEN-X announce a license agreement for therapeutic antibodies

Date: 18/02/2015

18 February 2015, Breda, The Netherlands – Lonza, a global leader in biological manufacturing and arGEN-X N.V. announced today that they have entered into a new, multi-product commercial license agreement for the production of arGEN-X’s therapeutic antibodies. (more…)

FABPulous successfully closes series B funding round and begins commercial activities

Date: 04/02/2015

4 February 2015, Maastricht – Today FABPulous announced the successful closure of their €1.8m Series B funding round by undisclosed new investors as well as some of the current investors. (more…)

Therasolve closes a EUR 2.4M series A financing round

Date: 22/01/2015

21 January 2015, Diepenbeek, Belgium – TheraSolve NV announces that it has recently closed an “A” financing round accounting for a total investment of EUR 2.4 million. (more…)

Hemics successfully closes new financing round and obtains CE marking

Date: 09/01/2015

9 January 2015, Eindhoven, The Netherlands – Hemics announces today that it received CE marking required for commercial sales of its medical device, the HandScan, and closed a new investment round, welcoming new investor DFZ Participaties. (more…)